Lenalidomide Drl 5 / 10 / 15 / 25 5 mg, 10 mg, 15 mg, 25 mg, Capsules
PDF Leaflet Revision Date: 14 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of myelodysplastic syndromes and multiple myeloma.
Dosage (summary)
MDS: 10 mg orally once daily for 21 days in 28-day cycles. Multiple Myeloma: 25 mg/day orally for 21 days in 28-day cycles.
Special Populations
- Elderly: No dose adjustments needed.
- Renal impairment: Dose adjustments required based on creatinine clearance.
Pregnancy & Breastfeeding
Contraindicated in pregnancy; teratogenic effects expected. Breastfeeding not recommended.
Key Drug Interactions
- Increased risk of VTE with dexamethasone.
- Caution with erythropoietic agents.
Contraindications
- Pregnancy and lactation.
- Hypersensitivity to lenalidomide.
Common side effects
- Neutropenia
- Thrombocytopenia
- Fatigue
- Diarrhea
- Rash
Counselling Points
- Use effective contraception during treatment.
- Regular pregnancy testing for women of childbearing potential.
- Report signs of infection or bleeding immediately.
Serious warnings
- Severe birth defects.
- Risk of thromboembolic events.
- Progressive multifocal leukoencephalopathy.
Important Disclaimer
The Lenalidomide Drl 5 / 10 / 15 / 25 5 mg, 10 mg, 15 mg, 25 mg, Capsules professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
